KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Income from Continuing Operations: 2018-2025

Historic Income from Continuing Operations for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Sep 2025 value amounting to $31.6 million.

  • Aurinia Pharmaceuticals' Income from Continuing Operations rose 120.53% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 443.39%. This contributed to the annual value of $5.7 million for FY2024, which is 107.36% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Income from Continuing Operations stood at $31.6 million, which was up 46.66% from $21.5 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Income from Continuing Operations' 5-year high stood at $31.6 million during Q3 2025, with a 5-year trough of -$50.4 million in Q1 2021.
  • For the 3-year period, Aurinia Pharmaceuticals' Income from Continuing Operations averaged around $368,545, with its median value being $678,000 (2024).
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Income from Continuing Operations tumbled by 312.71% in 2021, and later spiked by 3,073.01% in 2025.
  • Aurinia Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at -$33.3 million in 2021, then climbed by 21.84% to -$26.0 million in 2022, then fell by 3.34% to -$26.9 million in 2023, then soared by 105.47% to $1.5 million in 2024, then soared by 120.53% to $31.6 million in 2025.
  • Its last three reported values are $31.6 million in Q3 2025, $21.5 million for Q2 2025, and $23.3 million during Q1 2025.